{"disease":{"id":"primary-biliary-cholangitis-pbc","name":"primary biliary cholangitis pbc"},"drugs":{"marketed":[{"drug_id":"seladelpar","indication_name":"Primary Biliary Cholangitis (PBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Livdelzi","generic_name":"SELADELPAR","company_name":"Gilead Sciences Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":64,"revenue":"200","mechanism":"Livdelzi works by inhibiting the activity of a specific enzyme involved in the progression of liver disease."},{"drug_id":"seladelpar","indication_name":"primary biliary cholangitis (PBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Livdelzi","generic_name":"SELADELPAR","company_name":"Gilead Sciences Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":64,"revenue":"200","mechanism":"Livdelzi works by inhibiting the activity of a specific enzyme involved in the progression of liver disease."},{"drug_id":"elafibranor","indication_name":"Primary biliary cholangitis (PBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Iqirvo","generic_name":"ELAFIBRANOR","company_name":"Ipsen","drug_phase":"marketed","molecular_target":"","drug_class":"Peroxisome Proliferator-activated Receptor Agonist [EPC]","quality_score":60,"revenue":null,"mechanism":"Iqirvo works by activating peroxisome proliferator-activated receptors to improve liver function."}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07149675","title":"PBC Long-term Outcomes Study","phase":"","overall_status":"RECRUITING","enrollment_count":4000,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT07449793","title":"Biochemical Response and Clinical Outcomes in Patients With PBC","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT06016842","title":"A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":276,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT06591468","title":"A Multicenter, Randomized, Controlled Trial of Prednisone Combined With Ursodeoxycholic Acid in the Treatment of Primary Biliary Cholangitis With Moderate to Severe Interface Hepatitis Characteristics","phase":"PHASE2, PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":244,"lead_sponsor_name":"Han Ying","has_results":false},{"nct_id":"NCT07296458","title":"FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Xijing Hospital of Digestive Diseases","has_results":false},{"nct_id":"NCT07304843","title":"A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":84,"lead_sponsor_name":"Umecrine Cognition AB","has_results":false},{"nct_id":"NCT05896124","title":"CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":75,"lead_sponsor_name":"Cascade Pharmaceuticals, Inc","has_results":false},{"nct_id":"NCT07161245","title":"RELIEF: Multimodal Prehabilitation to Treat Fatigue in Patients With Primary Biliary Cholangitis","phase":"NA","overall_status":"RECRUITING","enrollment_count":64,"lead_sponsor_name":"Hospital Clinic of Barcelona","has_results":false},{"nct_id":"NCT03521297","title":"Probiotics in PBC Patients of Poor Response to UDCA","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03188146","title":"Performance of Scoring Systems in Chinese Patients With Primary Biliary Cholangitis (PBC) on Ursodeoxycholic Acid","phase":"","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"Humanity and Health Research Centre","has_results":false},{"nct_id":"NCT03124108","title":"Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Genfit","has_results":true},{"nct_id":"NCT06591455","title":"A Pilot Study of Fenofibrate and Ursodeoxycholic Acid in the Treatment of Newly Diagnosed Primary Biliary Cholangitis","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Han Ying","has_results":false},{"nct_id":"NCT06798454","title":"Single Ascending Dose Study to Evaluate Safety Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 in Healthy Subjects and Patients (PBC/PSC)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Parvus Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04047160","title":"Safety, Tolerability of OP-724 in Patients With Primary Biliary Cholangitis (Phase I)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"Kiminori Kimura, MD","has_results":false}],"total":14},"guidelines":[],"source":"Drug Landscape verified database"}